40results about "Sonopheresis" patented technology

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

Methods for enhancing intracellular uptake of active agents by inducing temporary pore formation in a cell membrane are described. The methods generally comprise introducing nanoparticles to a cell in vivo, ex vivo, or in cell culture to magnetic nanoparticles that are taken up into the cell interior. The methods further comprise introducing active agents to the cell. A magnetic field is applied to the cell for targeted excitation of the internalized magnetic nanoparticles to induce temporary pore formation in the cell membrane, such that the active agent is taken up in an increased amount and / or at an increased rate by the cell.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

The present invention, based on a non-bubble-based sonoporation technique, provides an ultrasound-assisted delivery platform for drug-loaded chitosan nanoparticles. This platform comprises: the administration of drug-loaded chitosan nanoparticles and the application of ultrasound stimulation. The drug-loaded chitosan nanoparticles are delivered to a target site, where ultrasound waves are directly applied to induce cellular membrane deformation. The ultrasound mechanical force temporarily alters membrane permeability, thereby facilitating the intracellular delivery of the drug-loaded chitosan nanoparticles.

A method of treating a target tissue area with a ribosome-inactivating protein. The method comprises injecting the target tissue area with an effective dose of a ribosome-inactivating protein and administering electroporation therapy to the target tissue area.

A method for monitoring the viability of stem cell-derived cells used in stem cell therapy, comprising: introducing one or more stem cell-derived cells into a cell culture medium; introducing one or more nanoprobes into the cell culture medium, thereby transfecting the one or more stem cell-derived cells with the one or more nanoprobes; and detecting an optical signal from the one or more nanoprobes after transfection. The method may further comprise administering the one or more transfected stem cell-derived cells to a subject and detecting an optical signal from the one or more nanoprobes in vivo. The one or more stem cell-derived cells may comprise stem cells.

Disclosed herein are vaccines comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods can comprise administering the vaccine to the subject in need thereof.

A novel localized, mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing the efficacy of therapeutics and increasing immune cell infiltration. A miniaturized dual-lumen catheter device is configured to deliver M-HIFU to a tumor that does not have the anatomic limitations of conventional HIFU, and enables access to a primary or metastatic tumor regardless of the location.

The application provides a targeted drug-loaded microbubble as well as a preparation method and application thereof, and belongs to the technical field of methods for preparing special forms of medicines. The targeted drug-loaded microbubble comprises a PEG shell, a lipid bilayer and a DBCO anchor point, the lipid bilayer is loaded with PTX, the lipid bilayer is located in the PEG shell, and the DBCO anchor point is located on the PEG shell. The targeted drug-loaded microbubble provided by the application can regulate the shape and size of the microbubble, is applied to ultrasonic contrast diagnosis imaging, has excellent targeted killing effect on tumors, and has good biological safety.

The invention belongs to the technical field of biomedicine, and particularly relates to a piezoelectric nanosheet for regulating and controlling distribution and expression of cell membrane protein and a preparation method of the piezoelectric nanosheet. The piezoelectric nanosheet is a bismuth oxyiodate layered nanosheet with an Aurivillius structure, and the surface of the piezoelectric nanosheet is modified by polyvinylpyrrolidone (PVP) and is abbreviated as BIOP; the nanosheet is synthesized by bismuth nitrate pentahydrate, potassium iodate and PVP through a hydrothermal method in one step, and the average size is 93 nm. BIOP can be attached to the surface of a cell, responds to ultrasonic irradiation with different intensities, generates a nanoscale periodic oscillation electric field, and performs electrostatic interaction with charged cell membrane protein on a cell membrane, so that the original hydrophobic force-electrostatic force balance steady state of the membrane protein is broken, internalization and degradation of the membrane protein are efficiently mediated, and regulation and control of distribution and expression of the cell membrane protein are realized. Compared with biochemical strategies such as antagonist drugs, gene editing and the like, the strategy has the unique advantages of being accurate and controllable, high in penetration depth and the like, and has important significance for revealing an intercellular communication mechanism and treating cell membrane protein dependent diseases.

The invention provides a neuroinflammation dual-targeting sound-sensitive liposome as well as a preparation method and application thereof. The neuroinflammation dual-targeting sound-sensitive liposome comprises a liposome, a sound-sensitive agent entrapped in the liposome and an antibody modified on the surface of the liposome, the sound-sensitive agent is benzothiadiazole-triphenylamine, and the structural formula of the sound-sensitive agent is shown in the specification. And the antibody comprises an anti-TMEM119 antibody and an anti-NAT antibody. The neuroinflammation dual-targeting sound-sensitive liposome can target sympathetic neurons and microglial cells at a neuroinflammation part, has a neural immune regulation effect under ultrasonic activation, can be used for preparing a diagnosis and treatment agent for diagnosis and treatment integration of myocardial ischemia reperfusion injury, and realizes diagnosis and treatment integration of myocardial ischemia reperfusion injury.

The present application relates to a DNAzyme nanomaterial synthesis method for treating tumors while maintaining fertility, which first synthesizes DNAzyme with an APE1 enzyme site, then mixes it with hemoglobin, a divalent iron solution and deionized water, forms a nanocomposite through vortexing, centrifuging and washing, and uses tannic acid to achieve encapsulation and preservation during synthesis. The novel nanocomposite synthesized by the present application can dissociate and play a role in tumor cells with high APE1 expression, but not in normal cells, achieving targeted treatment and effectively protecting reproductive organs; at the same time, the novel nanocomposite synthesized through ultrasonic and enzyme double control activation can achieve spatiotemporal controllable combined treatment of tumors, is used for tumor treatment while maintaining fertility, and avoids damage to reproductive organs.

A novel localized mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing efficacy of therapeutic drugs and increasing immune cell infiltration. A miniaturized dual lumen catheter device is configured to deliver M-HIFU to tumors, eliminating the anatomical limitations of conventional HIFU and allowing access to primary or metastatic tumors regardless of their location.

The present disclosure generally relates to technologies for treating cancer, including brain cancers such as a glioblastoma, methods of increasing the concentration of anthracy clines and immune checkpoint modulators in the brain of a subject, and methods of improving use of immune checkpoint modulators in brain cancers. Also disclosed herein are compositions and methods for treating a brain tumor.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

The present invention relates to a solution for use in electric field ablation of the urinary bladder wall for electroporation of urothelial carcinoma, as well as to a method for electric field ablation of the urinary bladder wall for electroporation of a urothelial carcinoma, in which the solution according to the invention is employed.

Methods and systems for improving or enabling delivery of antibodies, immunoglobulin receptors, or immunotherapy agents across the Blood-Brain Barrier (BBB) are disclosed. Exosomes are derived from stem cells, immune cell progenitors, or immune cells, and are loaded with an antibody, immunoglobulin receptor, or antibody fragment. Focused energy, preferably low-intensity focused ultrasound, is applied to a region of the BBB of a patient, and loaded exosomes are administered to the patient. Exosomes target the region for delivery of the loaded antibody, receptor, or fragment, either by traversing the BBB at the region or releasing the loaded antibody to neural tissue at the region.

The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions.

Methods and systems for improving or enabling delivery of antibodies, immunoglobulin receptors, or immunotherapy agents across the Blood-Brain Barrier (BBB) are disclosed. Exosomes are derived from stem cells, immune cell progenitors, or immune cells, and are loaded with an antibody, immunoglobulin receptor, or antibody fragment. Focused energy, preferably low-intensity focused ultrasound, is applied to a region of the BBB of a patient, and loaded exosomes are administered to the patient. Exosomes target the region for delivery of the loaded antibody, receptor, or fragment, either by traversing the BBB at the region or releasing the loaded antibody to neural tissue at the region.

Provided are nucleic acid delivery vectors configured to drive expression in multiple cell types, and methods of use. In some cases, the nucleic acid delivery vectors disclosed herein can prevent or reduce an immune response to a transgene expressed from a nucleic acid delivery vector, and which maintains expression of the transgene at a therapeutic level suitable for treating genetic disorders. One of the multiple cell types may be an LSEC.

A method for enhancing the effectiveness of therapeutic treatments mediated by ultrasound in combination with gas-filled microvesicles is provided. A vasospasm inhibitor is provided for use in enhancing the efficacy of a therapeutic treatment combining gas-filled microvesicles and therapeutic ultrasound, the method comprising the steps of: a) administering a vasospasm inhibitor to the vasculature of a subject; b) administering a suspension of gas-filled microvesicles to the vasculature of the subject; and c) applying therapeutic ultrasound to a region of interest in the subject.

A method for non-surgically reducing localized adipose tissue in a patient is provided. The method comprises topically administering to a site at or proximate adipose tissue, with massage at the site of administration, a composition comprising: at least one biologically compatible pharmacologically active detergent selected from the group consisting of a lipophilic detergent, a hydrophilic detergent, an ionic detergent, a non-ionic detergent, a zwitterionic detergent, a glyceride and a bile acid or salt thereof in a concentration ranging from about 0.5% to about 30% by wt of the composition and at least one phospholipid. In one embodiment, a novel composition comprising deoxycholic acid or a salt thereof at a concentration ranging from about 0.5% to about 30% by wt, and phosphatidylcholine at a concentration ranging from about 0.1% to about 2% by wt, in a cream base is also provided.

The present invention provides a pharmaceutical composition for treating obesity, the composition including: one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, and rubella virus; or a genetic material coding for a protein derived from these viruses. Preferably, the pharmaceutical composition is a vaccine composition. The composition provides a reduction in target tissues, preferably tissues containing adipocytes, or an effect that leads to the death of adipocytes.

Provided are a stem cell-nano anticancer drug complex in which an anticancer drug based on carbon nanotubes (CNT) and gold (Au) nano particles is loaded on the surface of stem cells, which can overcome side effects of conventional stem cells and targeting limitations of nano anticancer drugs and whose anticancer effect is very excellent, the use thereof, and a method for preparing the same.

The present invention relates to a solution for use in the electrical field ablation of the bladder wall for electroporation of urothelial carcinoma and to a method for the electrical field ablation of the bladder wall for electroporation of a urothelial carcinoma, in which the solution according to the invention is used.

The application belongs to the technical field of medical equipment, and provides a wearable electric heating patch, a preparation method and application thereof. The electric heating patch comprises an ion gel matrix and Mxene nanosheets doped therein. The ion gel matrix takes an ionic liquid as a dispersion medium. The electric heating patch has transparency. The preparation method comprises the following steps: mixing Mxene nanosheet material and ion gel precursors, and reacting in a mold under ultraviolet light irradiation to obtain the wearable electric heating patch with transparency. The wearable patch has good electrical conductivity, photothermal performance and good optical transparency. The electric heating patch can realize electric heating and photothermal synergistic treatment by simply applying an external current and light, has a quick response, can be used for a long time, and can realize real-time observation of the heating condition of the skin during the treatment process, so that the electric heating patch is suitable for use as a medical patch.

The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., microparticles comprising a core, a metal shell, and a metal / dielectric interface) and methods for delivering such particles via topical application.

Provided are methods and compositions for expressing a functional dystrophin protein or a functional fragment thereof in a subject. The method can include administering a nucleic acid encoding the dystrophin protein to the subject, administering a sonoactive agent to the subject, and applying ultrasound energy the cell. Also provided are use of a nucleic acid encoding a functional dystrophin protein and a sonoactive agent in a method of treating a subject having a dystrophinopathy disorder requiring a dystrophin gene therapy or a dystrophin protein replacement therapy.